LT2827863T - Skysta kompozicija, skirta panaudoti bendamustinui jautrių būklių gydymo būde pacientuose, kuriems reikalingi sumažinti įvedimo tūriai - Google Patents
Skysta kompozicija, skirta panaudoti bendamustinui jautrių būklių gydymo būde pacientuose, kuriems reikalingi sumažinti įvedimo tūriaiInfo
- Publication number
- LT2827863T LT2827863T LTEP13765020.6T LT13765020T LT2827863T LT 2827863 T LT2827863 T LT 2827863T LT 13765020 T LT13765020 T LT 13765020T LT 2827863 T LT2827863 T LT 2827863T
- Authority
- LT
- Lithuania
- Prior art keywords
- administration
- liquid composition
- patients requiring
- requiring reduced
- reduced volumes
- Prior art date
Links
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 title 1
- 229960002707 bendamustine Drugs 0.000 title 1
- 239000007788 liquid Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/12—Radicals substituted by oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261613173P | 2012-03-20 | 2012-03-20 | |
| US201261669889P | 2012-07-10 | 2012-07-10 | |
| US201261678715P | 2012-08-02 | 2012-08-02 | |
| PCT/US2013/032295 WO2013142359A1 (en) | 2012-03-20 | 2013-03-15 | Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT2827863T true LT2827863T (lt) | 2019-06-10 |
Family
ID=49212373
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEP13765020.6T LT2827863T (lt) | 2012-03-20 | 2013-03-15 | Skysta kompozicija, skirta panaudoti bendamustinui jautrių būklių gydymo būde pacientuose, kuriems reikalingi sumažinti įvedimo tūriai |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US9000021B2 (enExample) |
| EP (3) | EP3533447B1 (enExample) |
| JP (6) | JP6224064B2 (enExample) |
| CN (2) | CN104271135B (enExample) |
| CA (1) | CA2867343C (enExample) |
| DK (2) | DK2827863T3 (enExample) |
| ES (2) | ES2943668T3 (enExample) |
| FI (1) | FI3533447T3 (enExample) |
| HK (1) | HK1243346A1 (enExample) |
| HR (2) | HRP20190693T1 (enExample) |
| HU (2) | HUE044233T2 (enExample) |
| LT (1) | LT2827863T (enExample) |
| PL (2) | PL2827863T3 (enExample) |
| PT (2) | PT3533447T (enExample) |
| RS (2) | RS58744B1 (enExample) |
| SI (2) | SI2827863T1 (enExample) |
| WO (1) | WO2013142359A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE054836T2 (hu) | 2010-01-28 | 2021-10-28 | Eagle Pharmaceuticals Inc | Bendamusztin kiszerelései |
| JP6224064B2 (ja) | 2012-03-20 | 2017-11-01 | イーグル・ファーマシューティカルズ・インコーポレーテッド | 低減された投与容量を必要とする患者におけるベンダムスチン応答性症状の治療方法 |
| HRP20240056T1 (hr) * | 2012-03-20 | 2024-03-29 | Eagle Pharmaceuticals, Inc. | Formulacije bendamustina |
| US20230241218A1 (en) * | 2012-07-10 | 2023-08-03 | Eagle Pharmaceuticals, Inc. | Formulations of bendamustine |
| US11826466B2 (en) | 2016-08-31 | 2023-11-28 | Navinta, Llc | Bendamustine solution formulations |
| US10905677B2 (en) | 2016-08-31 | 2021-02-02 | Navinta, Llc | Bendamustine solution formulations |
| CA3108321A1 (en) | 2018-08-17 | 2020-02-20 | Hospira Australia Pty Ltd | Liquid bendamustine pharmaceutical compositions |
| US11730815B2 (en) * | 2018-11-26 | 2023-08-22 | Good Health, Llc | Stable liquid pharmaceutical compositions comprising bendamustine |
| JP7235288B2 (ja) * | 2019-01-07 | 2023-03-08 | コーアイセイ株式会社 | ベンダムスチンの液体製剤 |
| CN110123747A (zh) * | 2019-04-26 | 2019-08-16 | 嘉兴市爵拓科技有限公司 | 苯达莫司汀的制剂 |
| JPWO2021014957A1 (enExample) * | 2019-07-22 | 2021-01-28 | ||
| WO2021161876A1 (ja) * | 2020-02-10 | 2021-08-19 | 富士フイルム株式会社 | ベンダムスチン液剤 |
| US20240148696A1 (en) | 2022-10-25 | 2024-05-09 | Softkemo Pharma Inc. | Lyophilized bendamustine-cyclodextrin composition |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE159289C (enExample) | 1903-10-08 | 1905-03-16 | ||
| US4071620A (en) | 1977-01-10 | 1978-01-31 | American Home Products Corporation | Stabilization of oxygen sensitive dose forms |
| DD159289A1 (de) | 1981-06-01 | 1983-03-02 | Uwe Olthoff | Verfahren zur herstellung stabiler injektionsloesungen von n-lostverbindungen |
| DE3446873A1 (de) | 1984-12-21 | 1986-07-10 | Merckle Gmbh | Fluessige diclofenac-zubereitungen |
| US5223515A (en) | 1988-08-18 | 1993-06-29 | Takeda Chemical Industries, Ltd. | Injectable solution containing a pyridyl methylsulfinylbenzimidazole |
| NZ279443A (en) | 1994-01-24 | 1998-04-27 | Procter & Gamble | Solubilizing difficultly soluble pharmaceutical agents using a mixture of polyethylene glycol, polyvinylpyrrolidone and propylene glycol |
| EP1004305B1 (en) | 1998-04-20 | 2011-09-28 | Eisai R&D Management Co., Ltd. | Stabilized compositions containing benzimidazole-type compounds |
| WO2002032427A1 (en) | 2000-10-20 | 2002-04-25 | Galephar M/F | Stable oral formulation containing benzimidazole derivative |
| ES2300622T3 (es) | 2002-07-30 | 2008-06-16 | Wyeth | Formulaciones parenterales que contienen un hidroxiester de rapamicina. |
| US20060035945A1 (en) | 2003-05-30 | 2006-02-16 | Giorgio Attardo | Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases |
| SE0401842D0 (sv) * | 2004-07-12 | 2004-07-12 | Dizlin Medical Design Ab | Infusion and injection solution of levodopa |
| CA2585659A1 (en) | 2004-11-05 | 2006-06-22 | Cephalon, Inc. | Cancer treatments |
| US8436190B2 (en) | 2005-01-14 | 2013-05-07 | Cephalon, Inc. | Bendamustine pharmaceutical compositions |
| WO2007026771A1 (ja) * | 2005-08-31 | 2007-03-08 | Ono Pharmaceutical Co., Ltd. | 点滴用注射剤 |
| JPWO2008020584A1 (ja) | 2006-08-14 | 2010-01-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 安定な凍結乾燥製剤 |
| WO2008044029A1 (en) | 2006-10-12 | 2008-04-17 | Astex Therapeutics Limited | Pharmaceutical combinations |
| US8414909B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| DE102007003184A1 (de) | 2007-01-22 | 2008-07-24 | Orlowski, Michael, Dr. | Verfahren zur Beladung von strukturierten Oberflächen |
| US20090082416A1 (en) | 2007-09-25 | 2009-03-26 | Protia, Llc | Deuterium-enriched bendamustine |
| AR072777A1 (es) | 2008-03-26 | 2010-09-22 | Cephalon Inc | Formas solidas de clorhidrato de bendamustina |
| EP2889029A1 (en) * | 2008-09-25 | 2015-07-01 | Cephalon, Inc. | Liquid formulations of bendamustine |
| US8076366B2 (en) | 2009-01-15 | 2011-12-13 | Cephalon, Inc. | Forms of bendamustine free base |
| CA2753641C (en) | 2009-02-25 | 2014-09-16 | Supratek Pharma, Inc. | Bendamustine cyclopolysaccharide compositions |
| US20100273730A1 (en) * | 2009-04-27 | 2010-10-28 | Innopharmax, Inc. | Self-emulsifying pharmaceutical compositions of hydrophilic drugs and preparation thereof |
| EP2424506A1 (en) | 2009-04-28 | 2012-03-07 | Cephalon, Inc. | Oral formulations of bendamustine |
| CN101584668A (zh) * | 2009-06-19 | 2009-11-25 | 江苏奥赛康药业有限公司 | 盐酸苯达莫司汀冻干粉针剂 |
| WO2010148288A2 (en) | 2009-06-19 | 2010-12-23 | Lyotropic Therapeutics, Inc. | Pharmaceutical formulations with low aqueous levels of free unbound drug |
| US8389558B2 (en) | 2009-07-20 | 2013-03-05 | Supratek Pharma Inc. | Bendamustine amphiphilic anionic compositions |
| US20110015245A1 (en) | 2009-07-20 | 2011-01-20 | Valery Alakhov | Bendamustine amphiphilic cationic compositions |
| US7772274B1 (en) | 2009-10-19 | 2010-08-10 | Scidose, Llc | Docetaxel formulations with lipoic acid |
| HUE054836T2 (hu) | 2010-01-28 | 2021-10-28 | Eagle Pharmaceuticals Inc | Bendamusztin kiszerelései |
| US8604032B2 (en) * | 2010-05-21 | 2013-12-10 | Infinity Pharmaceuticals, Inc. | Chemical compounds, compositions and methods for kinase modulation |
| JP2013540104A (ja) | 2010-07-28 | 2013-10-31 | イーグル・ファーマシューティカルズ・インコーポレーテッド | 延長された保存安定性を有するペメトレキセドを含有する医薬組成物 |
| AU2012347972B2 (en) | 2011-12-05 | 2018-05-10 | X-Body, Inc. | PDGF receptor beta binding polypeptides |
| US20130210878A1 (en) * | 2012-01-24 | 2013-08-15 | Innopharma, Inc. | Bendamustine compositions and methods therefore |
| JP2015506989A (ja) | 2012-02-14 | 2015-03-05 | イーグル・ファーマシューティカルズ・インコーポレーテッド | ベンダムスチン製剤 |
| JP6224064B2 (ja) | 2012-03-20 | 2017-11-01 | イーグル・ファーマシューティカルズ・インコーポレーテッド | 低減された投与容量を必要とする患者におけるベンダムスチン応答性症状の治療方法 |
| HRP20240056T1 (hr) | 2012-03-20 | 2024-03-29 | Eagle Pharmaceuticals, Inc. | Formulacije bendamustina |
-
2013
- 2013-03-15 JP JP2015501814A patent/JP6224064B2/ja active Active
- 2013-03-15 SI SI201331394T patent/SI2827863T1/sl unknown
- 2013-03-15 PL PL13765020T patent/PL2827863T3/pl unknown
- 2013-03-15 DK DK13765020.6T patent/DK2827863T3/en active
- 2013-03-15 EP EP19151152.6A patent/EP3533447B1/en active Active
- 2013-03-15 RS RS20190433A patent/RS58744B1/sr unknown
- 2013-03-15 CA CA2867343A patent/CA2867343C/en active Active
- 2013-03-15 ES ES19151152T patent/ES2943668T3/es active Active
- 2013-03-15 PT PT191511526T patent/PT3533447T/pt unknown
- 2013-03-15 US US13/838,267 patent/US9000021B2/en active Active
- 2013-03-15 LT LTEP13765020.6T patent/LT2827863T/lt unknown
- 2013-03-15 CN CN201380023660.5A patent/CN104271135B/zh not_active Expired - Fee Related
- 2013-03-15 HU HUE13765020 patent/HUE044233T2/hu unknown
- 2013-03-15 HU HUE19151152A patent/HUE062230T2/hu unknown
- 2013-03-15 DK DK19151152.6T patent/DK3533447T3/da active
- 2013-03-15 CN CN201710292508.7A patent/CN107157988A/zh active Pending
- 2013-03-15 ES ES13765020T patent/ES2718902T3/es active Active
- 2013-03-15 PL PL19151152.6T patent/PL3533447T3/pl unknown
- 2013-03-15 WO PCT/US2013/032295 patent/WO2013142359A1/en not_active Ceased
- 2013-03-15 HR HRP20190693TT patent/HRP20190693T1/hr unknown
- 2013-03-15 PT PT13765020T patent/PT2827863T/pt unknown
- 2013-03-15 SI SI201332039T patent/SI3533447T1/sl unknown
- 2013-03-15 RS RS20230252A patent/RS64137B1/sr unknown
- 2013-03-15 HR HRP20230276TT patent/HRP20230276T1/hr unknown
- 2013-03-15 EP EP23161418.1A patent/EP4218756A1/en not_active Withdrawn
- 2013-03-15 EP EP13765020.6A patent/EP2827863B1/en active Active
-
2014
- 2014-11-26 US US14/554,269 patent/US20150080444A1/en not_active Abandoned
-
2015
- 2015-03-15 FI FIEP19151152.6T patent/FI3533447T3/fi active
- 2015-08-06 US US14/820,291 patent/US9579384B2/en active Active
-
2017
- 2017-10-04 JP JP2017193917A patent/JP6381761B2/ja active Active
-
2018
- 2018-02-28 HK HK18102930.9A patent/HK1243346A1/zh unknown
- 2018-07-31 JP JP2018143022A patent/JP6738376B2/ja active Active
-
2020
- 2020-05-29 JP JP2020093802A patent/JP2020143143A/ja active Pending
-
2021
- 2021-11-17 JP JP2021186829A patent/JP2022028813A/ja active Pending
-
2023
- 2023-12-15 JP JP2023212014A patent/JP2024037915A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE044233T2 (hu) | Folyékony készítmény bendamusztinra reagáló állapotok kezelési eljárásban történõ alkalmazásra, ahol a betegek csökkentett térfogatú bevitelre szorulnak | |
| IL249991A0 (en) | Methods of treating sick children by dexmedetomidine | |
| GB2524689B (en) | Cannabinoids for use in the treatment of neuropathic pain | |
| EP2788075A4 (en) | DEVICE AND METHOD FOR REDUCING THE TRANSTHORACOID IMPEDANCE OF A PATIENT | |
| SG11201403991RA (en) | Device for compartmental dilatation of blood vessels | |
| PL2773648T3 (pl) | Związki farmaceutyczne do zastosowania w terapii zakażenia clostridium difficile | |
| PL2644215T3 (pl) | Aparat do pozaustrojowej obróbki krwi | |
| GB2523055B8 (en) | Ophthalmic devices for delivery of beneficial agents | |
| PL395112A1 (pl) | Zastosowanie klenbuterolu do leczenia autyzmu | |
| GB201218084D0 (en) | Novel compounds and methods for use in medicine | |
| ZA201408993B (en) | Pharmaceutical formulation for bedwetting and method of use thereof | |
| EP2832434A4 (en) | METHOD FOR TREATING SIMULTANEOUS CAVITATION OF LIQUID MEDIA OF DIFFERENT COMPOSITIONS | |
| GB201121940D0 (en) | Drug treating high blood pressure | |
| ZA201307058B (en) | Use of polyaminoisoprenyl derrivatives in antobiotic or antisertic treatment | |
| GB2499319C (en) | Apparatus for administering fluid to a medical tube | |
| GB2508897B (en) | Oxygen flow controller for medical use | |
| EP2803672A4 (en) | Means for aligning liquid crystals | |
| IL212725A (en) | Glycerol Preparation for Non-surgical Conjunctivochalysis | |
| IL231531A (en) | Use of strigolactones and their analogues for the preparation of drugs for the treatment of cancerous growth conditions | |
| HUP1100245A2 (en) | Pharmaceutical composition for the treatment of wounds | |
| GB201209198D0 (en) | Liquid treatment | |
| GB201209283D0 (en) | Liquid treatment | |
| PH32012000869S1 (en) | Containing and applying tool for liquid medicine | |
| IL210808A0 (en) | System and method for treatment of liquid | |
| PL394852A1 (pl) | Urzadzenie do zageszczania miodu w stanie plynnym lub pólplynnym |